Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Peripheral Blood Stem Cells

Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases

Abstract

Donation-related data for 1488 allogeneic peripheral blood stem cell (PBSC) transplants reported to the International Bone Marrow Transplant Registry (IBMTR) or the European Blood and Marrow Transplant Group (EBMT) by 152 teams worldwide between 1994 and 1998 were reviewed. In 1998, 26% of allografts registered with the IBMTR were collected from blood. Median age of PBSC donors was 38 years (range <1–76), and 55% were male. Of 1486 donor–recipient pairs evaluable for HLA compatibility, 1322 (89%) were HLA-identical siblings. Recombinant human granulocyte colony-stimulating factor (G-CSF) was employed to mobilize PBSCs in almost all (99%) cases. One hundred and seventy (20%) of 828 evaluable PBSC donors had a central catheter placed for leukapheresis. Eighty-five percent of 1321 evaluable PBSC grafts were collected with one or two leukaphereses. There were 15 reported donation-related adverse events (1% of evaluable donors). Complications were catheter-related in five. No donation-related fatalities were reported. These data suggest that PBSC donation is becoming more prevalent worldwide. It appears to have a safety profile comparable to marrow harvesting, although experience with the latter is much more extensive. Bone Marrow Transplantation (2001) 27, 689–692.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Goldman J . Peripheral blood stem cells for allografting Blood 1995 85: 1413–1415

    CAS  PubMed  Google Scholar 

  2. Russell N, Gratwohl A, Schmitz N . The place of blood stem cells in allogeneic transplantation Br J Haematol 1996 93: 747–753

    Article  Google Scholar 

  3. Lane TA . Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era Transfusion 1996 36: 585–589

    Article  CAS  PubMed  Google Scholar 

  4. Bishop MR, Tarantolo SR, Jackson JD et al. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor J Clin Oncol 1997 15: 1601–1607

    Article  CAS  PubMed  Google Scholar 

  5. Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation Blood 1996 88: 2794–2800

    CAS  PubMed  Google Scholar 

  6. Brown RA, Adkins D, Goodnough LT et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies J Clin Oncol 1997 15: 3067–3074

    Article  CAS  PubMed  Google Scholar 

  7. Martinez C, Urbano-Ispizua A, Rozman C et al. Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors Ann Hematol 1996 72: 269–272

    Article  CAS  PubMed  Google Scholar 

  8. Dreger P, Haferlach T, Eckstein V et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft Br J Haematol 1994 87: 609–613

    Article  CAS  PubMed  Google Scholar 

  9. Russell JA, Luider J, Weaver M et al. Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors Bone Marrow Transplant 1995 15: 111–115

    CAS  PubMed  Google Scholar 

  10. Stroncek DF, Clay ME, Petzoldt ML et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells Transfusion 1996 36: 601–610

    Article  CAS  PubMed  Google Scholar 

  11. Buckner CD, Clift RA, Sanders JE et al. Marrow harvesting from normal donors Blood 1984 64: 630–634

    CAS  PubMed  Google Scholar 

  12. Bortin MM, Buckner CD . Major complications of marrow harvesting for transplantation Exp Hematol 1983 11: 916–921

    CAS  PubMed  Google Scholar 

  13. Stroncek DF, Holland PV, Bartch G et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program Blood 1993 81: 1940–1946

    CAS  PubMed  Google Scholar 

  14. Anderlini P, Körbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors Blood 1997 90: 903–908

    CAS  PubMed  Google Scholar 

  15. Anderlini P, Donato M, Chan KW et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the MD Anderson Cancer Center experience Transfusion 1999 39: 555–560

    Article  CAS  PubMed  Google Scholar 

  16. Majolino I, Cavallaro AM, Bacigalupo A et al. Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO) Haematologica 1997 82: 47–52

    CAS  PubMed  Google Scholar 

  17. Luider J, Brown C, Selinger S et al. Factors influencing yields of progenitor cells for allogeneic transplantation: optimization of G-CSF dose, day of collection, and duration of leukapheresis J Hematother 1997 6: 575–580

    Article  CAS  PubMed  Google Scholar 

  18. Lane TA, Law P, Maruyama M et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte–macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation Blood 1995 85: 275–282

    CAS  PubMed  Google Scholar 

  19. Vij R, Brown RA, Adkins D et al. Mobilization of normal donors with G-CSF + GM-CSF is associated with improved yield of hematopoietic progenitors and increased numbers of activated dendritic cells (abstract) Blood 1998 92: 682a

    Google Scholar 

  20. Parkkali T, Volin L, Siren MK et al. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor Bone Marrow Transplant 1996 17: 433–434

    CAS  PubMed  Google Scholar 

  21. Becker PS, Wagle M, Matous S et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells Biol Blood Marrow Transplant 1997 3: 45–49

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by Public Health Service Grants P01-CA-40053 and U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute, of the US Department of Health and Human Services; and grants from Amgen, Inc.; Anonymous; Baxter Fenwal; Berlex Laboratories; Blue Cross and Blue Shield Association; Lynde and Harry Bradley Foundation; Bristol-Myers Squibb Oncology; Cell Therapeutics; Center for Advanced Studies in Leukemia; Chimeric Therapies; Chiron Therapeutics; COBE BCT Inc.; Eleanor Naylor Dana Charitable Trust; Deborah J Dearholt Memorial Fund; Empire Blue Cross Blue Shield; Eppley Foundation for Research; Fromstein Foundation; Fujisawa Healthcare, Inc.; Genentech, Inc.; Hoechst Marion Roussel; Horizon Medical Products; Human Genome Sciences; IDEC Pharmaceuticals; Immunex Corporation; IMPATH/BIS; IntraBiotics Pharmaceuticals; Kaiser Permanente; Kettering Family Foundation; Kirin Brewery Company; Robert J Kleberg, Jr and Helen C Kleberg Foundation; Herbert H Kohl Charities; Life Trac/Allianz; The Liposome Company; Nada and Herbert P Mahler Charities; Market Certitude; Mayer Ventures; MDS Nordian; MedImmune, Inc.; Milliman & Robertson, Inc.; Milstein Family Foundation; Miltenyi Biotech; Milwaukee Foundation/ Elsa Schoeneich Research Fund; Mutual of Omaha; Nexell Therapeutics; NeXstar Pharmaceuticals, Inc; Samuel Roberts Noble Foundation; Novartis Pharmaceuticals; Orphan Medical; Ortho Biotech, Inc.; John Oster Family Foundation; Jane and Lloyd Pettit Foundation; Pfizer, Inc.; Pharmacia and Upjohn; Principal Life Insurance Company; Protide Pharmaceuticals; RGK Foundation; Rhône-Poulenc Rorer Pharmaceuticals, Inc.; Roche Laboratories; SangStat Medical Corporation; Schering AG; Schering-Plough Oncology; Searle; SmithKline Beecham Pharmaceutical; Stackner Family Foundation; The Starr Foundation; StemCell Technologies; SyStemix; Therakos; TheraTechnologies; United Resource Networks; US Oncology; and Wyeth-Ayerst Laboratories.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderlini, P., Rizzo, J., Nugent, M. et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 27, 689–692 (2001). https://doi.org/10.1038/sj.bmt.1702875

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702875

Keywords

This article is cited by

Search

Quick links